Dendrimers as drugs: Discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention

被引：236

作者：

McCarthy, Tom D. ^{[1
]}

Karellas, Peter ^{[1
]}

Henderson, Scott A. ^{[1
]}

Giannis, Michael ^{[1
]}

O'Keefe, David F. ^{[1
]}

Heery, Graharn ^{[1
]}

Paull, Jeremy R. A. ^{[1
]}

Matthews, Barry R. ^{[1
]}

Holan, George ^{[1
]}

机构：

[1] Starpharma Pty Ltd, Melbourne, Vic 3004, Australia

来源：

MOLECULAR PHARMACEUTICS | 2005年 / 2卷 / 04期

关键词：

nanoscale; nanotechnology; chemical diversity; molecular diversity; dendrimer; SPL7013; VivaGel; antiviral; HIV; HSV-2; microbicide;

D O I：

10.1021/mp050023q

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Starpharma focuses on the use of dendrimers as drugs in their own right, in contrast to dendrimers as drug delivery vehicles or diagnostics. This contextual review describes how dendrimers offer a unique platform for exploring chemical diversity on the nanoscale and how the production of dendrimer libraries covering a diverse array of macromolecular structures can be used in drug discovery and development. Using Starpharma's work on the prevention of HIV and sexually transmitted infections (STIs) through the development of microbicide candidates as an example, the process from which SPL7013 emerged as a development candidate is described. Following a range of preclinical studies, Starpharma submitted an investigational new drug application (IND) for SPL7013 gel (VivaGel) to the United States Food and Drug Administration (FDA) in June 2003, the first such submission for a dendrimer-based drug. The first clinical trial under this IND was completed in 2004.

引用

页码：312 / 318

页数：7

共 25 条

[11] Evidence of dual sites of action of dendrimers: SPL-2999 inhibits both virus entry and late stages of herpes simplex virus replication [J].